These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16145036)

  • 1. Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor.
    Thompson IM; Canby-Hagino E; Lucia MS
    J Natl Cancer Inst; 2005 Sep; 97(17):1236-7. PubMed ID: 16145036
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate cancer and the Will Rogers phenomenon.
    Albertsen PC; Hanley JA; Barrows GH; Penson DF; Kowalczyk PD; Sanders MM; Fine J
    J Natl Cancer Inst; 2005 Sep; 97(17):1248-53. PubMed ID: 16145045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact?
    Andriole GL; Humphrey PA; Serfling RJ; Grubb RL
    J Natl Cancer Inst; 2007 Sep; 99(18):1355-6. PubMed ID: 17848666
    [No Abstract]   [Full Text] [Related]  

  • 4. Gleason scoring system faces change and debate.
    Schmidt C
    J Natl Cancer Inst; 2009 May; 101(9):622-9. PubMed ID: 19401555
    [No Abstract]   [Full Text] [Related]  

  • 5. Invited commentary: Prostate cancer: doing less might be more. Comment on "Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer".
    Ablin RJ; Sartor O; Bennett CL
    Arch Intern Med; 2010 Aug; 170(15):1397-9. PubMed ID: 20696969
    [No Abstract]   [Full Text] [Related]  

  • 6. [New developments in diagnosis and therapy of prostate cancer--from "active surveillance" to robotic-assisted surgery].
    Krome S
    Dtsch Med Wochenschr; 2011 Oct; 136 Suppl 3():S86-9. PubMed ID: 21960373
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of recent trends in prostate cancer incidence and mortality.
    Dennis LK; Resnick MI
    Prostate; 2000 Mar; 42(4):247-52. PubMed ID: 10679753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
    Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
    J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing prostate cancer: new analyses put finasteride back on the map.
    Vastag B
    J Natl Cancer Inst; 2008 Aug; 100(16):1132-3. PubMed ID: 18695128
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
    Miller DC; Gruber SB; Hollenbeck BK; Montie JE; Wei JT
    J Natl Cancer Inst; 2006 Aug; 98(16):1134-41. PubMed ID: 16912266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer.
    Daskivich T; Sadetsky N; Kaplan SH; Greenfield S; Litwin MS
    Arch Intern Med; 2010 Aug; 170(15):1396-7. PubMed ID: 20696968
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Aurélien Descazeaud, Marc Zerbib, Thierry Flam et al. Can pT0 stage of prostate cancer be predicted before radical prostatectomy? Eur Urol 2006;50:1248-53.
    Montironi R; Scarpelli M; Lopez-Beltran A; Cheng L
    Eur Urol; 2007 Jul; 52(1):294-5. PubMed ID: 17383812
    [No Abstract]   [Full Text] [Related]  

  • 14. Prediction of outcomes after radical prostatectomy in patients diagnosed with prostate cancer of biopsy Gleason score ≥ 8 via contemporary multi (≥ 12)-core prostate biopsy.
    Hong SK; Oh JJ; Jeong SJ; Jeong CW; Kim IS; Park JM; Byun SS; Choe G; Lee HJ; Lee SE
    BJU Int; 2011 Jul; 108(2):217-22. PubMed ID: 21083642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Haines IE; Gabor Miklos GL
    J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary cancer and relapse rates following radical prostatectomy for prostate-confined cancer.
    Wesley D; Cox HF
    J Insur Med; 2007; 39(4):242-50. PubMed ID: 18522141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer.
    Gallina A; Chun FK; Suardi N; Eastham JA; Perrotte P; Graefen M; Hutterer G; Huland H; Klein EA; Reuther A; Montorsi F; Briganti A; Shariat SF; Roehrborn CG; de la Taille A; Salomon L; Karakiewicz PI
    BJU Int; 2008 Jun; 101(12):1513-8. PubMed ID: 18422773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current methods of radical treatment for localized prostate cancer].
    Kaprin AD; Khmelevskiĭ EV; Fadeev AV
    Vopr Onkol; 2008; 54(1):108-12. PubMed ID: 18416071
    [No Abstract]   [Full Text] [Related]  

  • 19. Radical prostatectomy as treatment for prostate cancer.
    Jewett MA; Fleshner N; Klotz LH; Nam RK; Trachtenberg J
    CMAJ; 2003 Jan; 168(1):44-5. PubMed ID: 12515785
    [No Abstract]   [Full Text] [Related]  

  • 20. Population-based study of long-term survival in patients with clinically localised prostate cancer.
    Lu-Yao GL; Yao SL
    Lancet; 1997 Mar; 349(9056):906-10. PubMed ID: 9093251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.